Basic Science and Instrumentation Scientific Session 3
Can We Accelerate Therapeutical Response Assessment in Metastatic Renal Carcinoma with Novel Long Ensemble Doppler Ultrasound Sequences?
Tuesday, April 9, 2024
4:41pm – 4:53pm
Authors: Sergio Sanabria, Stanford University, Department of Radiology Neha Antil, Stanford University Aya Kamaya, Stanford
Metastatic Renal Carcinoma (mRCC) is the 8th most common cancer in the U.S., with a 5-year survival rate of 12%. Combinations of anti-angiogenesis and immunotherapy offer new opportunities for improving response rate and survival outcomes. Yet, current assessment of therapy response is only performed after 12 weeks of therapy based on tumor size changes, which can lead to unnecessary duration of ineffective treatment, with potential adverse events associated to treatment toxicity.
We postulate that ultrasound can non-invasively provide early indicators of tumor response in a shorter period of 3 and 6 weeks. Decrease of tumor perfusion in Doppler Ultrasound images can be quantified as an indicator of tumor response. Cutting edge long-ensemble ultrasound sequences based on Ultrafast-Doppler imaging and coherence of the RF signal boost Doppler sensitivity and improve vessel resolution.
Using these sequences, sensitive quantitative biomarkers to separate responder and non-responders can be identified after 3 weeks (1 biomarker) and 6 weeks (3 biomarkers).